Avoid common mistakes on your manuscript.
Correction to: Cancer Immunology, Immunotherapy https://doi.org/10.1007/s00262-021-03008-0
The original version of this article unfortunately contained a mistake. Author name Titus Watrin was incorrectly written as Titus Vatrin.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Reusing, S.B., Vallera, D.A., Manser, A.R. et al. Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL. Cancer Immunol Immunother 70, 3709 (2021). https://doi.org/10.1007/s00262-021-03040-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-021-03040-0